Pharmaceuticals, Biotechnology and Life Sciences
Boston Harbor Hotel, Boston, MA, June 5-6, 2019 PRINCETON, N.J.–(BUSINESS WIRE)–The Avoca Group today announced the preliminary agenda for its…
LONDON–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Research?src=hash" target="_blank"gt;#Researchlt;/agt;–Technavio has announced the release of their research report on the global bioreactors market for the forecast…
DUBLIN–(BUSINESS WIRE)–The “Traditional and Emerging Spectroscopy Techniques in Life Sciences” report has been added to ResearchAndMarkets.com’s offering. The study covers…
Targets Liver Cancer JENKINTOWN, Pa.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/HCC?src=hash" target="_blank"gt;#HCClt;/agt;–SFA Therapeutics today announced approval of the second key U.S. patent derived from…
CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Rex Medical, L.P., a medical device design and development company, today announced the successful completion of enrollment in…
SEATTLE–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24CMI&src=ctag" target="_blank"gt;$CMIlt;/agt; lt;a href="https://twitter.com/hashtag/InjectableGenerics?src=hash" target="_blank"gt;#InjectableGenericslt;/agt;–According to Coherent Market Insights, the global specialty injectable generics market was valued at…
DUBLIN–(BUSINESS WIRE)–The “Amblyopia Global Clinical Trials Review, H2, 2018” clinical trials has been added to ResearchAndMarkets.com’s offering. Amblyopia Global Clinical…
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),today announced that the U.S. Food and Drug Administration (FDA)approved Tecentriq® (atezolizumab), in combinationwith carboplatin and etoposide (chemotherapy), for the initial(first-line) treatment of adults with extensive-stage small cell lungcancer (ES-SCLC).
DUBLIN–(BUSINESS WIRE)–The “Duchenne Muscular Dystrophy Treatment Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to…
Aptar Pharma, a leading drug delivery systems provider, is pleased to announce that its Bidose nasal spray device was recently approved by the U.S. FDA for a breakthrough therapy in the field of depression.